The IC-8® Apthera™ intraocular lens is the first and only small aperture lens for cataract surgery
LAGUNA HILLS, Calif., February 6, 2023 (Newswire.com)
-
Harvard Eye Associates, a multi-specialty ophthalmology practice, implanted the first IC-8® Apthera™ intraocular lens (IOL) in Orange County, CA, since U.S. FDA approval of this new implant. The Apthera™ lens is the first and only small aperture lens for cataract surgery designed to help patients receive extended depth of focus because of its unique optics.
The FDA-approved Apthera™ IOL has a FilterRing™ component that creates a small aperture to adjust the amount of light entering the eye. It filters out unfocused light that can cause blurry vision and allows focused light to enter the retina. This provides a continuous range of vision allowing patients to see from near, through intermediate, to distance.
The Apthera™ IOL is intended for use in one eye with a monofocal or monofocal toric IOL in the fellow eye. This combination is based on the patient's visual needs and can be customized to achieve their best personal results. It has also been shown to help cataract patients that have a low amount of astigmatism (as much as 1.5 diopters).
"This new lens represents a major new offering for people undergoing cataract surgery because it can help them see a range of vision, which previous single-focus were unable to do. Furthermore, this lens may be particularly appropriate for people who have had previous eye surgery like Lasik or RK. It's based on a very simple and well-understood concept from photography--that a small opening in a lens can increase depth of field greatly. Our experience implanting this lens in the studies that led to FDA approval was extremely positive, and we know it will be popular with patients," said Dr. John Hovanesian, one of the board-certified cataract surgeons at Harvard Eye Associates.
Harvard Eye Associates, also an active FDA research center, was involved in the clinical trial of the Apthera™ IOL and has extensive experience with this new lens.
Harvard Eye now offers cataract patients this advanced replacement lens. Patients interested in cataract surgery with the Apthera™ IOL may contact Harvard Eye by calling 949-951-2020 or visiting harvardeye.com.
Contact Information:
Erica Arrington
Marketing & Business Development Manager [email protected]
(949)900-5228
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacologythat demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.
"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).
The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of insilico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.